scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer

Abstract Background Clinical trials have shown that neoadjuvant anlotinib combined with PD-1 blockade therapy can prolong the survival of patients with driver gene negative non-small cell lung cancer (NSCLC), but some patients fail to benefit from the combination therapy. Methods To explore the pote...

Full description

Bibliographic Details

Published in:	Journal of Translational Medicine
Main Authors:	Ziqi Huang, Li Li, Xiaohe Zhao, Haixia Jin, Meng Shen, Baihui Li, Yu Zeng, Qinfen Zhang, Qiyu Wang, Meng Wang, Lili Yang
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Subjects:	Neoadjuvant immunotherapy Anlotinib PD-1 blockade NSCLC Tumor microenvironment Single-cell
Online Access:	https://doi.org/10.1186/s12967-025-06485-4